Navigation Links
Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged
Date:9/10/2008

Mega-dose Resveratrol, Sirtuin1 gene Target Discredited; Lower Dose, Array

of Small Molecules (Longevinex(R)) Exert Greater Effect

SAN DIMAS, Calif., Sept. 10 /PRNewswire/ -- While the red wine molecule resveratrol (rez-vair-ah-trawl) has recently attracted scientific and public attention as a longevity molecule that allegedly mimics the effects of a calorie-restricted diet, the science surrounding this molecule has taken a dramatic turn in recent months, according to Bill Sardi, spokesperson for Longevinex(R) (long-jev-in-ex), a major brand resveratrol supplement.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU004)

Published research studies now show:

-- Mice fed high-dose resveratrol did not live as long as mice fed a plain standard calorie diet. Animals on the lower dose (360 milligram human equivalent) lived longer than those on the higher dose (1565 mg) of resveratrol. [Resveratrol Delays Age-Related Deterioration and Mimics Transcriptional Aspects of Dietary Restriction without Extending Life Span. Cell Metabolism 2008 Aug;8(2):157-68]

-- The Sirtuin1 gene, once called the "holy grail" of longevity and believed to be the gene target of calorie restriction, has not been found to be universally activated by a limited calorie diet. A calorie-restricted diet results in more Sirtuin1 gene-derived proteins by exerting stabilization effects, not by activation of the gene. This new finding throws a scientific cloud over the use of Sirtuin1 gene activation tests as a measure of resveratrol activity. [Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev. 2008 Jul 1; 22(13):1753-7; Regulation of SIRT1 protein levels by nutrient availability. FEBS Letters. 2008 Jul 9; 582(16):2417-23]

-- While researchers once advised consumers to wait for stronger synthetic molecules that can stimulate the Sirtuin1 gene by 1
'/>"/>

SOURCE Resveratrol Partners, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
2. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
3. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
4. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
5. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
6. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
7. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
8. Stem Cell Sciences Announces the Creation of the Worlds First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology
9. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
10. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , 21 de noviembre de 2014 /PRNewswire/ ... ensayos clínicos externalizados y tecnologías eClinical, ha indicado ... de ,seguimiento inteligente, para el seguimiento basado en ... inteligente amplía el concepto del seguimiento basado en ... de las visitas de seguimiento o cambio de ...
(Date:11/22/2014)... Nov. 21, 2014 MEDITE Group acquired by CytoCore, ... and the 3 rd quarter sales ended September 30, ... $448,000 for the nine months ended September 2014 and a ... our 3 rd quarter is usually a seasonable weak ... July into September for many countries worldwide, we are proud ...
(Date:11/22/2014)... Nov. 21, 2014 Many power shifts ... growing influence of patients in the biopharmaceutical market ... Now, more than ever, understanding how to effectively ... products is essential. According to ... benchmarked companies spent about two-thirds of their patient-focused ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... , NEW YORK, ... research report is available in its catalogue: , ... , http://www.reportlinker.com/p0164212/Chiral-Technology---International-Technology--Market-Trends.html , The fast developing ... of activity with pharmaceutical companies adding chiral expertise to ...
... , NEW YORK, ... research report is available in its catalogue: , ... of Market Trends & Opportunities , http://www.reportlinker.com/p0164272/Hepatitis-C-Virus-And-Therapeutics---A-Global-Update-of-Market-Trends--Opportunities.html ... years of meager clinical outcomes owing to lack of ...
Cached Medicine Technology:Reportlinker Adds Chiral Technology - International Technology & Market Trends 2Reportlinker Adds Chiral Technology - International Technology & Market Trends 3Reportlinker Adds Chiral Technology - International Technology & Market Trends 4Reportlinker Adds Chiral Technology - International Technology & Market Trends 5Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 8
(Date:11/22/2014)... November 22, 2014 Recently, UWDress.com is ... wedding guest dresses . In addition, the company has ... , As a leading online supplier of wedding ... beautiful outfits. The unusual best wedding guest gowns are ... the amazing designs, this new selection is famous for ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Sandbridge ... equity investments in the consumer brand sector, acquired ... investment will be used to help fund BackJoy’s ... pipeline rollout, particularly its proprietary apparel and footwear ... join BackJoy’s Board of Directors. , BackJoy is ...
(Date:11/22/2014)... “Greenfield Naturals” was featured on NewsWatch as ... features the latest and coolest technology products available to ... NewsWatch, conducted the product review and shared with viewers ... water. , From pollution to hazardous substances in water, ... done to remove these chemicals, especially in water. , ...
(Date:11/22/2014)... 21, 2014 (HealthDay News) -- A clinical trial of ... been halted a year early because the results show ... the disease and reduce the risk of stroke. ... 25 medical centers in the United States and Canada, ... Lung, and Blood Institute (NHLBI). Researchers compared monthly ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... better when patients are treated in an ambulance by a ... researchers report. The sooner patients get the clot dissolver ... after a stroke, the researchers noted. For the best outcome, ... after stroke symptoms start, the researchers said. "The so-called ...
Breaking Medicine News(10 mins):Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Sickle Cell Anemia Treatment So Successful in Kids That Trial Is Halted 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... Jan. 27 Bio-Reaction Industries, LLC (BRI),received the ... Special,Services by the Environmental Business Journal for 2008. ... Bio-Reactions progression as a worldwide leader of,bio-oxidation technology. ... amazing growth in 2008, increasing,revenue by 300% for ...
... 9% Over 2007 to $765.3 Million; Positive Operating Cash ... 27 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... year ended December 31, 2008. The Company reported total ... 31, 2008, which includes net product sales of $184.9 ...
... imperative of addressing chronic disease crisisWASHINGTON, Jan. 27 ... today urged President Obama and Congress to make ... components of reform efforts. Topping its list of ... leaders to realign incentives in the health care ...
... researchers say , , TUESDAY, Jan. 27 (HealthDay News) -- ... potential new method of promoting recovery from chronic stress ... "fight or flight" response. , The approach focuses on ... body,s major control systems. The HPA axis uses hormone ...
... Chest radiation indicates need for earlier screening, study notes, ... of female childhood cancer survivors under the age of ... treatment are not following the recommended advice to get ... , The recommendation suggests starting screening mammograms at age ...
... Calif., Jan. 27 Omnicell, Inc.,(Nasdaq: OMCL ) ... been awarded a five year contract by Duke University ... , Duke University Health ... Hospital, Duke Raleigh Hospital, and many other clinical,facilities. , ...
Cached Medicine News:Health News:Bio-Reaction Industries Recognized as Leader in Technology 2Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 2Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 3Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 4Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 5Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 6Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 7Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 8Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 9Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 10Health News:National Partnership Releases Principles for Meaningful Health Reform 2Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 2Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 3Health News:Omnicell is Awarded Contract by Major National Academic Medical Center 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: